{"altmetric_id":4689887,"selected_quotes":["$IMNP Phase 2 trial w\/est Feb completion date NCT02226146: Trial Tracker","@Overstew Bullous pemphigoid phase 2a Ulcerative colitis phase 2a","$IMNP Phase 2 trial w\/est Mar completion date NCT02226146: Trial Tracker","@DogFoodDog BP trial: Aug PR said $IMNP will add 5 US centers. Trial has 19 weeks for screening\/treatment\/follow-up","@aschwartzphd $IMNP BP trial record updated: changed from 2 to 3 IV infusions. Follow-up was 6 weeks, now 13"],"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Immune Pharmaceuticals"],"first_seen_on":"2015-10-28T13:27:33+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1490991062,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02226146","http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02226146?lup_d=365&lup_s=11%2F11%2F2013&recr=Open&sel_rss=mod14&show_rss=Y&term=Pemphigoid"],"nct_id":"NCT02226146","pubdate":"2014-07-27T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid","type":"clinical_trial_study_record"},"altmetric_score":{"score":85,"score_history":{"1y":1.5,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":85},"context_for_score":{"all":{"total_number_of_other_articles":8440126,"mean":7.0979478654558,"rank":106584,"this_scored_higher_than_pct":98,"this_scored_higher_than":8333488,"rank_type":"exact","sample_size":8440126,"percentile":98},"similar_age_3m":{"total_number_of_other_articles":245959,"mean":9.7959119280526,"rank":5557,"this_scored_higher_than_pct":97,"this_scored_higher_than":240395,"rank_type":"exact","sample_size":245959,"percentile":97},"this_journal":{"total_number_of_other_articles":24887,"mean":10.554611106646,"rank":446,"this_scored_higher_than_pct":98,"this_scored_higher_than":24440,"rank_type":"exact","sample_size":24887,"percentile":98},"similar_age_this_journal_3m":{"total_number_of_other_articles":1132,"mean":14.812152077807,"rank":35,"this_scored_higher_than_pct":96,"this_scored_higher_than":1097,"rank_type":"exact","sample_size":1132,"percentile":96}}},"demographics":{"poster_types":{"member_of_the_public":3},"users":{"twitter":{"cohorts":{"Members of the public":3}}},"geo":{"twitter":{"US":2}}},"counts":{"total":{"posts_count":23},"news":{"unique_users_count":11,"unique_users":["seeking_alpha","yahoo_finance_usa","bioportfolio","finanz_nachrichten","stock_nod_quotes","minyanville_finance","yahoo_finance_singapore","nasdaq","wall_street_online_germany","fresh_news","stockhouse"],"posts_count":13},"twitter":{"unique_users_count":3,"unique_users":["RDTrials","fda_tracker","TomMathies"],"posts_count":10}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/RDTrials\/status\/532128323736842240","license":"datasift","citation_ids":[4689887],"posted_on":"2014-11-11T11:10:53+00:00","author":{"name":"Clinical Trials RD","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_5_normal.png","id_on_source":"RDTrials","tweeter_id":"971840539","geo":{"lt":null,"ln":null},"followers":7},"tweet_id":"532128323736842240"},{"url":"https:\/\/twitter.com\/fda_tracker\/status\/564802117492166656","license":"datasift","citation_ids":[4689887],"posted_on":"2015-02-09T15:04:52+00:00","author":{"name":"FDA Tracker","url":"http:\/\/www.fdatracker.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1667207308\/square_logo_normal.png","description":"Analytics for Pharma and Biotech Traders","id_on_source":"fda_tracker","tweeter_id":"391492257","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":2985},"tweet_id":"564802117492166656"},{"url":"http:\/\/twitter.com\/fda_tracker\/statuses\/697058629220827136","license":"gnip","citation_ids":[4689887],"posted_on":"2016-02-09T14:05:02+00:00","author":{"name":"FDA Tracker","url":"http:\/\/www.fdatracker.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1667207308\/square_logo_normal.png","description":"Analytics for Pharma and Biotech Traders","id_on_source":"fda_tracker","tweeter_id":"391492257","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":2985},"tweet_id":"697058629220827136"},{"url":"http:\/\/twitter.com\/TomMathies\/statuses\/700306213037346816","license":"gnip","citation_ids":[4689887],"posted_on":"2016-02-18T13:09:46+00:00","author":{"name":"Tom Mathies","url":"http:\/\/seekingalpha.com\/author\/tom-mathies","image":"https:\/\/pbs.twimg.com\/profile_images\/882421950009798656\/rIo01b4i_normal.jpg","description":"Prairie enthusiast, also healthcare stocks","id_on_source":"TomMathies","tweeter_id":"358759878","geo":{"lt":42.99083,"ln":-89.53318,"country":"US"},"followers":472},"tweet_id":"700306213037346816"},{"url":"http:\/\/twitter.com\/TomMathies\/statuses\/774648374612025344","license":"gnip","citation_ids":[4689887],"posted_on":"2016-09-10T16:38:59+00:00","author":{"name":"Tom Mathies","url":"http:\/\/seekingalpha.com\/author\/tom-mathies","image":"https:\/\/pbs.twimg.com\/profile_images\/882421950009798656\/rIo01b4i_normal.jpg","description":"Prairie enthusiast, also healthcare stocks","id_on_source":"TomMathies","tweeter_id":"358759878","geo":{"lt":42.99083,"ln":-89.53318,"country":"US"},"followers":472},"tweet_id":"774648374612025344"},{"url":"http:\/\/twitter.com\/TomMathies\/statuses\/795647298701234176","license":"gnip","citation_ids":[4689887],"posted_on":"2016-11-07T15:21:13+00:00","author":{"name":"Tom Mathies","url":"http:\/\/seekingalpha.com\/author\/tom-mathies","image":"https:\/\/pbs.twimg.com\/profile_images\/882421950009798656\/rIo01b4i_normal.jpg","description":"Prairie enthusiast, also healthcare stocks","id_on_source":"TomMathies","tweeter_id":"358759878","geo":{"lt":42.99083,"ln":-89.53318,"country":"US"},"followers":472},"tweet_id":"795647298701234176"},{"url":"http:\/\/twitter.com\/TomMathies\/statuses\/824631762504523777","license":"gnip","citation_ids":[4689887],"posted_on":"2017-01-26T14:55:07+00:00","author":{"name":"Tom Mathies","url":"http:\/\/seekingalpha.com\/author\/tom-mathies","image":"https:\/\/pbs.twimg.com\/profile_images\/882421950009798656\/rIo01b4i_normal.jpg","description":"Prairie enthusiast, also healthcare stocks","id_on_source":"TomMathies","tweeter_id":"358759878","geo":{"lt":42.99083,"ln":-89.53318,"country":"US"},"followers":472},"tweet_id":"824631762504523777"},{"url":"http:\/\/twitter.com\/TomMathies\/statuses\/836715522079272963","license":"gnip","citation_ids":[4689887],"posted_on":"2017-02-28T23:11:40+00:00","author":{"name":"Tom Mathies","url":"http:\/\/seekingalpha.com\/author\/tom-mathies","image":"https:\/\/pbs.twimg.com\/profile_images\/882421950009798656\/rIo01b4i_normal.jpg","description":"Prairie enthusiast, also healthcare stocks","id_on_source":"TomMathies","tweeter_id":"358759878","geo":{"lt":42.99083,"ln":-89.53318,"country":"US"},"followers":472},"tweet_id":"836715522079272963"},{"url":"http:\/\/twitter.com\/fda_tracker\/statuses\/843810612236902400","license":"gnip","citation_ids":[4689887],"posted_on":"2017-03-20T13:05:01+00:00","author":{"name":"FDA Tracker","url":"http:\/\/www.fdatracker.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1667207308\/square_logo_normal.png","description":"Analytics for Pharma and Biotech Traders","id_on_source":"fda_tracker","tweeter_id":"391492257","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":2985},"tweet_id":"843810612236902400"},{"url":"http:\/\/twitter.com\/TomMathies\/statuses\/847904089124065280","license":"gnip","citation_ids":[4694280,4689887],"posted_on":"2017-03-31T20:11:02+00:00","author":{"name":"Tom Mathies","url":"http:\/\/seekingalpha.com\/author\/tom-mathies","image":"https:\/\/pbs.twimg.com\/profile_images\/882421950009798656\/rIo01b4i_normal.jpg","description":"Prairie enthusiast, also healthcare stocks","id_on_source":"TomMathies","tweeter_id":"358759878","geo":{"lt":42.99083,"ln":-89.53318,"country":"US"},"followers":472},"tweet_id":"847904089124065280"}],"news":[{"title":"Immune Pharmaceuticals: 5 Big Warning Signs","url":"http:\/\/ct.moreover.com\/?a=25558094354&p=1pl&v=1&x=qj5GQVtGtjD6LHmFUoMg4A","license":"public","citation_ids":[4689887,4694280,5969043],"posted_on":"2016-02-22T20:55:36+00:00","summary":"Immune Pharmaceuticals (NASDAQ: IMNP ) has a terrific story. Its drug bertilimumab inhibits eotaxin-1, a protein that regulates allergic responses, and thus has the potential to be an effective treatment for an array of inflammatory diseases\u2026","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}},{"title":"IMNP: Phase 2 Clinical Trials of Bertilimumab Ongoing; Subsidiary to Develop Immunooncology Products.\u2026","url":"http:\/\/ct.moreover.com\/?a=26095394500&p=1pl&v=1&x=jXKXPeGf4MSmbzZ-ZuU6LA","license":"public","citation_ids":[4689887,649927,4694280,6572170,4319451,3221409,2413922,1006853,6536997,3383623,6015766],"posted_on":"2016-04-07T17:25:00+00:00","summary":"By 1 hour ago By David Bautz, PhD NASDAQ:IMNP Financial Update On March 30, 2016, Immune Pharmaceuticals, Inc.","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"Delving Deep into Immune Pharmaceuticals' Diverse Pipeline","url":"http:\/\/ct.moreover.com\/?a=26417081587&p=1pl&v=1&x=XgF9aNOWUL8r_7Lr1R_Z6A","license":"public","citation_ids":[4689887,4694280,3952164,7219709],"posted_on":"2016-05-04T00:00:00+00:00","summary":"Immune Pharmaceuticals Inc. is a clinical-stage. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human IgG4 antibody, which is currently in Phase 2 clinical trials for the treatment of inflammatory\u2026","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"Analyst Jason Napodano Discusses Immune Pharmaceuticals in Article for The Life Sciences Report","url":"http:\/\/ct.moreover.com\/?a=26422432095&p=1pl&v=1&x=qw2veeZVIQeUM27YPDcDpQ","license":"public","citation_ids":[4689887],"posted_on":"2016-05-05T13:01:00+00:00","summary":") - Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer.","author":{"name":"Finanz Nachrichten","url":"http:\/\/www.finanznachrichten.de","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/853\/normal\/Screen_Shot_2016-01-27_at_11.54.22.png?1453895724"}},{"title":"Analyst Jason Napodano Discusses Immune Pharmaceuticals in Article for The Life Sciences Report","url":"http:\/\/ct.moreover.com\/?a=26422475449&p=1pl&v=1&x=RYeI4TAYACrBRPtdJk5UlA","license":"public","citation_ids":[4689887],"posted_on":"2016-05-05T13:00:00+00:00","summary":") - Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer.","author":{"name":"Stock Nod: Quotes","url":"http:\/\/quotes.stocknod.com\/stocknod","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/671\/normal\/Screen_Shot_2016-01-26_at_13.59.47.png?1453816868"}},{"title":"Analyst Jason Napodano Discusses Immune Pharmaceuticals in Article for The Life Sciences Report","url":"http:\/\/ct.moreover.com\/?a=26422494957&p=1pl&v=1&x=kX44rSPTDaoRqW4W1tjrJQ","license":"public","citation_ids":[4689887],"posted_on":"2016-05-05T13:00:00+00:00","summary":"SAN FRANCISCO, CA--(Marketwired - May 05, 2016) - Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer.","author":{"name":"Minyanville: Finance ","url":"http:\/\/finance.minyanville.com\/minyanville","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/637\/normal\/Screen_Shot_2016-02-02_at_16.44.51.png?1454431502"}},{"title":"Analyst Jason Napodano Discusses Immune Pharmaceuticals in Article for The Life Sciences Report","url":"http:\/\/ct.moreover.com\/?a=26422520363&p=1pl&v=1&x=O0-14HVeyYKuDmXMYeZ5xw","license":"public","citation_ids":[4689887],"posted_on":"2016-05-05T13:00:00+00:00","summary":") - Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer.","author":{"name":"Yahoo! Finance Singapore","url":"http:\/\/sg.finance.yahoo.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/721\/normal\/Screen_Shot_2016-01-26_at_15.33.41.png?1453822448"}},{"title":"Analyst Jason Napodano Discusses Immune Pharmaceuticals in Article for The Life Sciences Report","url":"http:\/\/ct.moreover.com\/?a=26422528134&p=1pl&v=1&x=t3as5OgRgqbjTaorw1fzxQ","license":"public","citation_ids":[4689887],"posted_on":"2016-05-05T01:00:00+00:00","summary":"SAN FRANCISCO, CA -- (Marketwired) -- 05\/05\/16 -- Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer.","author":{"name":"NASDAQ","url":"http:\/\/www.nasdaq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/839\/normal\/Screen_Shot_2016-01-27_at_11.14.52.png?1453893369"}},{"title":"Analyst Jason Napodano Discusses Immune Pharmaceuticals in Article for The Life Sciences Report","url":"http:\/\/ct.moreover.com\/?a=26422547628&p=1pl&v=1&x=3vFbB2mf41NlkSeAKPSPWw","license":"public","citation_ids":[4689887],"posted_on":"2016-05-05T13:13:27+00:00","summary":") - Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer.","author":{"name":"Wall Street Online Germany","url":"http:\/\/www.wallstreet-online.de","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/837\/normal\/Screen_Shot_2016-01-27_at_11.09.05.png?1453893177"}},{"title":"Analyst Jason Napodano Discusses Immune Pharmaceuticals in Article for The Life Sciences Report","url":"http:\/\/ct.moreover.com\/?a=26422592131&p=1pl&v=1&x=zBhWV0A88GvYdcdmDf3vqA","license":"public","citation_ids":[4689887],"posted_on":"2016-05-05T13:00:00+00:00","summary":") - Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer.","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"Analyst Jason Napodano Discusses Immune Pharmaceuticals in Article for The Life Sciences Report","url":"http:\/\/ct.moreover.com\/?a=26422810157&p=1pl&v=1&x=00WY9djHGEt6iRGpie1mzg","license":"public","citation_ids":[4689887],"posted_on":"2016-05-05T13:00:00+00:00","summary":") - Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer.","author":{"name":"Fresh News","url":"http:\/\/www.freshnews.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/833\/normal\/Screen_Shot_2016-01-27_at_10.59.49.png?1453892431"}},{"title":"Analyst Jason Napodano Discusses Immune Pharmaceuticals in Article for The Life Sciences Report","url":"http:\/\/ct.moreover.com\/?a=26423022691&p=1pl&v=1&x=mCj9eu8DSD4VrOUyyJwFxw","license":"public","citation_ids":[4689887],"posted_on":"2016-05-05T00:00:00+00:00","summary":"SAN FRANCISCO, CA--(Marketwired - May 05, 2016) - Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer.","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"Delving deep into Immune Pharmaceuticals' diverse pipeline","url":"http:\/\/ct.moreover.com\/?a=26431497662&p=1pl&v=1&x=MZLdstWxPBrfMawKpWm20g","license":"public","citation_ids":[4689887,4694280,3952164,7219709],"posted_on":"2016-05-06T06:51:57+00:00","summary":"Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer.","author":{"name":"Stockhouse","url":"http:\/\/www.stockhouse.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/768\/normal\/Screen_Shot_2016-01-26_at_16.49.41.png?1453827072"}}]}}